Joan Perelló, Sanifit CEO

Joan Perel­ló set out 17 years ago to de­vel­op a drug. And to­day he's be­ing re­ward­ed with a $424M biotech buy­out

Joan Perel­ló beat all the odds with his lit­tle Span­ish biotech start­up San­i­fit.

Work­ing on the far perime­ter of the big US/Eu­ro­pean drug de­vel­op­ment scene, he took a drug born out of his PhD work and got enough seed cash to get start­ed. That’s one near mir­a­cle. In the sec­ond near mir­a­cle he gath­ered a pre­vi­ous­ly un­heard of ven­ture raise in Spain — help­ing build an in­dus­try ecosys­tem from scratch — to pur­sue a suc­cess­ful search for sol­id hu­man da­ta for his drug, SNF472. And while gath­er­ing a vir­tu­al team of de­vel­op­ers from Eu­rope and the US, the CEO/co-founder steered it in­to the late-stage are­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.